Quantcast
Last updated on April 18, 2014 at 17:24 EDT

Latest Mammaprint Stories

2012-01-05 08:00:00

IRVINE, Calif. and AMSTERDAM, Jan. 5, 2012 /PRNewswire/ -- Agendia, an innovative molecular cancer diagnostics company, today announced that the company has signed a contract with Blue Shield of California, making Agendia an in-network provider. The move paves the way for future in-network coverage for MammaPrint® and other Agendia tests by Blue Cross affiliates across the United States. Developed and commercialized by Agendia, MammaPrint is the keystone of the company's...

2011-12-19 15:08:16

As a woman ages, her chances of being diagnosed with a lower-risk breast tumor increase, according to a novel study led by UCSF which found that for women over 50, a substantial number of cancers detected by mammograms have good prognoses. The study provides the first molecular evidence of an increase in low- or ultra-low-risk cancers in the tumors when detected by screening mammography. And it provides a basis for integrating molecular profiling at the time of diagnosis to help avoid...

2011-12-06 08:00:00

IRVINE, Calif. and AMSTERDAM, Dec. 6, 2011 /PRNewswire/ -- Agendia, an innovative molecular diagnostics company, today announced the introduction of formalin fixed, paraffin embedded tissue technology applied to their Symphony(TM) suite of breast cancer assays. Delivering Agendia's tests in a paraffin embedded tissue format offers their customers added convenience along with the superior science, development and validation found in Agendia's breast cancer Symphony suite....

2011-12-06 08:00:00

IRVINE, Calif. and AMSTERDAM, Dec. 6, 2011 /PRNewswire/ -- Agendia, a world leader in molecular cancer diagnostics, announced today that leading company researchers will present data from multiple studies in five poster presentations at the 2011 San Antonio Breast Cancer Symposium (SABCS). The San Antonio Breast Cancer Symposium, one of the premiere conferences in breast cancer research worldwide, takes place December 6th - 10th, 2011. Agendia's studies to be presented at SABCS 2011 will...

2011-11-08 07:00:00

REDWOOD CITY, Calif., Nov. 8, 2011 /PRNewswire/ -- Genomic Health, Inc. today announced that the Journal of Clinical Oncology (JCO) published positive results from the landmark QUASAR clinical validation study, which demonstrated that the Oncotype DX® colon cancer test predicts recurrence risk in stage II colon cancer patients following surgery. The findings, published today online as an "early release," also establishes that the Oncotype DX colon cancer Recurrence...

2011-10-18 08:00:00

BRUSSELS, IRVINE, California, and AMSTERDAM, October 18, 2011 /PRNewswire/ -- The EORTC, BIG, and Agendia, a commercial-stage molecular cancer diagnostics company, today announced the completion of patient registration for the EORTC 10041/BIG3-04 MINDACT (Microarray In Node negative and 1-3 positive lymph node Disease may Avoid Chemotherapy Trial) study. More than 6,600 patients in 111 institutions across nine countries were enrolled from February 2007 to July 2011 in this...

2011-10-03 08:00:00

IRVINE, California and AMSTERDAM, October 3, 2011 /PRNewswire/ -- Agendia, an innovative molecular cancer diagnostics company, today announced that the company successfully completed a recent, routine inspection of its Irvine, California-based laboratories by the US Food and Drug Administration (FDA). Agendia received FDA 510(k) clearance for its MammaPrint(R) breast cancer recurrence test in early 2007. It remains the first and only test of its kind to receive FDA clearance,...

2011-09-19 08:00:00

IRVINE, California and AMSTERDAM, September 19, 2011 /PRNewswire/ -- Agendia, an innovative molecular cancer diagnostics company, today announced that a published report highlighting the development and validation of its 80-gene BluePrint breast cancer profile was published online in Breast Cancer Research and Treatment, a peer-reviewed publication. BluePrint is a part of Agendia's Symphony(TM) suite of breast cancer products, a comprehensive collection of genetic assays that...

2011-08-10 08:00:00

IRVINE, California and AMSTERDAM, August 10, 2011 /PRNewswire/ -- Agendia, a commercial-stage molecular cancer diagnostics company, today announced that the 12th St. Gallen International Breast Cancer Conference (2011) Expert Panel's recommendations highlight the value of molecular subtyping - classifying patients by the particular biological subtype of their tumor - in guiding treatment decisions for breast cancer patients. According to the panel, "it is no longer tenable to...

2011-07-21 08:00:00

IRVINE, California and AMSTERDAM, July 21, 2011 /PRNewswire/ -- Agendia, a global innovator in molecular cancer diagnostics, announced today that, together with thought-leading collaborators in clinical centers and translational research groups, it has launched the RATHER (Rational Therapy for Breast Cancer) and COLTHERES (Colon Cancer and Therapeutics) consortiums. The partnerships will collectively receive nearly EUR12 million in funding from the European Union's 7th Framework...